

Community Tissue Services (CTS) utilizes patented Allowash® Treatment, which is specially designed to facilitate the removal of cellular elements from musculoskeletal tissue while maintaining structural integrity. The Allowash® Treatment utilizes both mechanical and chemical methodologies to reduce the potential danger of disease transmission. This treatment, along with a rigorous donor screening process, has been designed and validated to increase the safety of allograft tissue.

## Allowash® Treatment was extensively studied for its effect on processed allograft tissue and the following conclusions were drawn:

- Allowash<sup>®</sup> Treatment provides for up to a 3-log reduction in residuals of bone marrow and blood elements through cleaning. Through the disinfection process, Allowash<sup>®</sup> Treatment provides a 9-20 log reduction in microorganisms and a 2.2-12.4 log viral reduction. When coupled with Community Tissue Services strict donor screening and testing, these log reductions in bone marrow, blood elements, bacteria and viruses by Allowash® Treatment, provide for a high level of safety for CTS allograft tissues.
- Allowash<sup>®</sup> Treatment results in biocompatible allografts for your clinical applications. Allowash<sup>®</sup> solution (detergent based) is twice as effective in solubilizing bone marrow as detergent solutions used by other tissue processors, yet it is not cytotoxic to mammalian cells. Allowash® Treatment removes greater than 99% of this processing solution.
- ✓ Bone and soft tissue grafts processed using the Allowash<sup>®</sup> Treatment do not induce adverse inflammatory responses when implanted.
- Allowash<sup>®</sup> Treatment does not affect the osteoinductivity or osteoconductivity of bone allografts.
- ✓ A study evaluating the Allowash<sup>®</sup> Treatment on the biomechanical properties of small structural, weight-bearing allografts (including iliac crest wedges and Cloward dowels) demonstrated that the biomechanical strength of structural allografts subjected to Allowash® Treatment was not altered.
- ✓ A study evaluating Allowash<sup>®</sup> Treatment on the biomechanical properties of connective tissue allografts (including fascia lata, patellar ligament, and achilles tendons) demonstrated that the tensile strength of the grafts subjected was not altered.

Allowash® is a registered trademark of LifeNet Health. Products and processes may be covered by one or more of the following U.S. patents: 6,024,735, 5,977,432, 5,977,034, 5,976,104, 5,820,581, 5,797,871, and 5,556,379. CTS licenses the Allowash® Service from LifeNet Health, Virginia Beach, VA. Rev 00